e136 860
in distinct biological and molecular contexts. Oncotarget 2017;8:
48905–14.
[5]
Carey LA, Berry DA, Cirrincione CT, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016;34:542–9.Pontus Eriksson
a
Gottfrid Sjo¨dahl
b
Fredrik Liedberg
b,
*
a
Department Clinical Sciences, Division of Oncology and Pathology, Lund
University, Lund University Hospital, Lund, Sweden
b
Department of Translational Medicine, Lund University, Ska˚ne University
Hospital, Malmo¨, Sweden
*Corresponding author. Department of Translational Medicine, Lund
University, Ska˚ ne University Hospital, Malmo¨ SE-20502, Sweden.
Tel. +46 40 331941; Fax: +46 40 333752.
E-mail address:
fredrik.liedberg@med.lu.se(F. Liedberg).
May 15, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 1 3 5 – e 1 3 6
e136